MedPath

ReXceptor Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2014-02-13
Last Posted Date
2015-08-13
Lead Sponsor
ReXceptor, Inc.
Target Recruit Count
12
Registration Number
NCT02061878
Locations
🇺🇸

Compass Research, Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath